Opinion

Video

Treatment in Early Relapse Multiple Myeloma: Takeaways from EHA 2024

Author(s):

Joseph Mikhael, MD

Dr. Mikhael discusses treatment in early relapse of multiple myeloma.

Video content above is prompted by the following question:

  • Please discuss recent updates presented at EHA 2024 in early-relapse multiple myeloma from CARTITUDE-4, KARMMA-2, DREAMM-7, and DREAMM-8.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Saad Z. Usmani, MD, MBA, FACP, FASCO, MSKCC
4 experts in this video
Related Content
The model has the potential to boost early detection of MM and contribute to a paradigm shift in the treatment of MM. | Image credit: shidlovski - stock.adobe.com
August 15th 2025

Model Based on EHR Parameters Can Predict 5-Year Multiple Myeloma Risk

Jared Kaltwasser
Joseph Mikhael, MD | Image: T-GEN
August 15th 2025

How M-Power Is Building Trust to Raise Awareness of Multiple Myeloma in the Black Community

Joseph Mikhael, MD Interview by Mary Caffrey
In follow-up PET/CTs, the investigators said those with complete metabolic remissions tended to have superior PFS. | Image credit: Saiful52 - stock.adobe.com
August 15th 2025

PET/CT Helps Predict Relapse in Patients With Myeloma Undergoing CAR T-Cell Therapy

Jared Kaltwasser
Black, Hispanic, and Pacific Islander patients generally experienced worse OS compared with White patients, while Asian patients had similar outcomes. | Image credit: Colored Lights - stock.adobe.com
August 15th 2025

Survival Gains in Multiple Myeloma Highlight Progress and Persistent Disparities

Kimberly Rath, PharmD
Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic
August 15th 2025

Sequencing CAR T and Bispecifics for Multiple Myeloma: Tyler Sandahl, PharmD

Cameron Santoro
Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic
August 15th 2025

Driving Value via Outcomes-Based Pricing and EHR Interoperability: Tyler Sandahl, PharmD

Cameron Santoro

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo